Pharmacokinetic modelling of N-(4-[18F]fluorobenzoyl) interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 10, 2012, Pages 1551-1560

  Di Gialleonardo, Valentina ^a,b   Signore, Alberto ^a,b,c   Willemsen, Antoon T M ^a   Sijbesma, Jurgen W A ^a   Dierckx, Rudi A J O ^a   De Vries, Erik F J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

18F FB IL2; Inflammation; Molecular imaging; Pharmacokinetics

Indexed keywords

INTERLEUKIN 2 RECEPTOR ALPHA; N (4 FLUOROBENZOYL)INTERLEUKIN 2 F 18; PHYTOHEMAGGLUTININ; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BINDING; HUMAN; HUMAN CELL; INFLAMMATION; LIMIT OF DETECTION; LYMPHOCYTE ACTIVATION; METABOLITE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA CONCENTRATION-TIME CURVE; POSITRON EMISSION TOMOGRAPHY; RAT; XENOGRAFT;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, WISTAR; TRANSPLANTATION, HETEROLOGOUS;

EID: 84868197748     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2176-y     Document Type: Article

References (27)

1. Benczik M, Gaffen SL. The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes. Immunol Invest 2004;33(2):109-42.
2. Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine 2004;28(3):109-23.
3. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010;33 (2):153-65.
4. Meyer KC. The role of immunity and inflammation in lung senescence and susceptibility to infection in the elderly. Semin Respir Crit Care Med 2010;31(5):561-74.
5. Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev 2011;10(3):319-29.
6. Vasto S, Candore G, Balistreri CR, Caruso M, Colonna-Romano G, Grimaldi MP, et al. Inflammatory networks in ageing, agerelated diseases and longevity. Mech Ageing Dev 2007;128 (1):83-91.
7. Marincheva-Savcheva G, Subramanian S, Qadir S, Figueroa A, Truong Q, Vijayakumar J, et al. Imaging of the aortic valve using fluorodeoxyglucose positron emission tomography increased valvular fluorodeoxyglucose uptake in aortic stenosis. J Am Coll Cardiol 2011;57(25):2507-15.
8. Yetkin E, Waltenberger J. Molecular and cellular mechanisms of aortic stenosis. Int J Cardiol 2009;135(1):4-13.
9. Ghiringhelli F, Ménard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 2006;214:229-38.
10. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A 2008;105(2):652-6.
11. Yoshioka K, Ueno Y, Tanaka S, Nagai K, Onitake T, Hanaoka R, et al. Role of natural killer T cells in the mouse colitis-associated colon cancer model. Scand J Immunol 2012;75(1):16-26.
12. Rangwala S, Tsai KY. Roles of the immune system in skin cancer. Br J Dermatol 2011;165(5):953-65.
13. Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 2008;18(1):3-10.
14. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454(7203):436-44.
15. Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008;267(2):204-15.
16. Chianelli M, Mather SJ, Martin-Comin J, Signore A. Radiopharmaceuticals for the study of inflammatory processes: a review. Nucl Med Commun 1997;18(5):437-55.
17. Chianelli M, Signore A, Fritzberg AR, Mather SJ. The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nucl Med Biol 1997;24(6):579-86.
18. D'Alessandria C, diGialleonardoV, Chianelli M,Mather SJ, deVries EF, Scopinaro F, et al. Synthesis and optimization of the labeling procedure of 99mTc-HYNIC-interleukin-2 for in vivo imaging of activated T lymphocytes. Mol Imaging Biol 2010;12(5):539-46.
19. Signore A, Chianelli M, Toscano A, Monetini L, Ronga G, Nimmon CC, et al. A radiopharmaceutical for imaging areas of lymphocytic infiltration: 123I-interleukin-2. Labelling procedure and animal studies. Nucl Med Commun 1992;13(10):713-22.
20. Signore A, Chianelli M, Annovazzi A, Bonanno E, Spagnoli LG, Pozzilli P, et al. 123I-interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease. J Nucl Med 2000;41(2):242-9.
21. Signore A, Picarelli A, Annovazzi A, Britton KE, Grossman AB, Bonanno E, et al. 123I-Interleukin-2: biochemical characterization and in vivo use for imaging autoimmune diseases. Nucl Med Commun 2003;24(3):305-16.
22. Di Gialleonardo V, Signore A, Glaudemans AWJM, Dierckx RA, De Vries EF. N-(4-18F-Fluorobenzoyl)interleukin-2 for PET of human-activated T lymphocytes. J Nucl Med 2012;53:679-86. doi:10.2967.
23. Bøyum A. Separation of white blood cells. Nature 1964;204:793-4.
24. Bøyum A. Separation of blood leucocytes, granulocytes and lymphocytes. Tissue Antigens 1974;4(4):269-74.
25. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007;27 (9):1533-9.
26. Akaike H. Data analysis by statistical models. No To Hattatsu 1992;24(2):127-33.
27. Donohue JH, Rosenberg SA. The fate of interleukin-2 after in vivo administration. J Immunol 1983;130(5):2203-8.